Attached files
| file | filename |
|---|---|
| 10-K - 10-K - CALADRIUS BIOSCIENCES, INC. | clbs-10kx20191231.htm |
| EX-32 - EXHIBIT 32 - CALADRIUS BIOSCIENCES, INC. | clbs-ex32_20191231.htm |
| EX-31.2 - EXHIBIT 31.2 - CALADRIUS BIOSCIENCES, INC. | clbs-ex312_20191231xq4.htm |
| EX-31.1 - EXHIBIT 31.1 - CALADRIUS BIOSCIENCES, INC. | clbs-ex311_20191231xq4.htm |
| EX-23.1 - EXHIBIT 23.1 - CALADRIUS BIOSCIENCES, INC. | exh2312019.htm |
| EX-4.3 - EXHIBIT 4.3 - CALADRIUS BIOSCIENCES, INC. | exh43.htm |
Exhibit 21.1
Subsidiaries of Caladrius Biosciences, Inc.
Entity | Percentage of Ownership | Location | ||
Amorcyte, LLC | 100% | United States of America | ||
Athelos Corporation (1) | 99% | United States of America | ||
NeoStem Oncology, LLC | 100% | United States of America | ||
(1) As of December 31, 2019, Becton Dickinson's ownership interest in Athelos Corporation was 1.0%.